IRIS
CAZZOLA, MARIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 59.482
AS - Asia 9.217
EU - Europa 6.715
SA - Sud America 1.330
Continente sconosciuto - Info sul continente non disponibili 715
AF - Africa 110
OC - Oceania 40
Totale 77.609
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 59.076
SG - Singapore 3.994
CN - Cina 2.109
BR - Brasile 1.080
IT - Italia 985
UA - Ucraina 977
RU - Federazione Russa 939
HK - Hong Kong 864
IE - Irlanda 768
DE - Germania 686
VN - Vietnam 661
FR - Francia 558
KR - Corea 556
GB - Regno Unito 437
PL - Polonia 435
FI - Finlandia 361
BD - Bangladesh 273
JP - Giappone 228
CA - Canada 221
SE - Svezia 210
NL - Olanda 135
IN - India 102
ID - Indonesia 80
AR - Argentina 71
MX - Messico 56
ES - Italia 48
IQ - Iraq 48
EC - Ecuador 45
CO - Colombia 38
AT - Austria 35
MY - Malesia 33
CR - Costa Rica 30
PH - Filippine 30
PK - Pakistan 30
TR - Turchia 29
AU - Australia 28
BE - Belgio 27
CL - Cile 26
UZ - Uzbekistan 26
ZA - Sudafrica 24
SA - Arabia Saudita 21
VE - Venezuela 21
PE - Perù 20
IL - Israele 19
JM - Giamaica 19
TH - Thailandia 19
EG - Egitto 18
MA - Marocco 17
A2 - ???statistics.table.value.countryCode.A2??? 15
PY - Paraguay 15
NG - Nigeria 14
PT - Portogallo 14
AE - Emirati Arabi Uniti 13
EU - Europa 12
GR - Grecia 12
JO - Giordania 12
NZ - Nuova Zelanda 12
HN - Honduras 10
SV - El Salvador 10
CH - Svizzera 9
GT - Guatemala 9
IR - Iran 9
TT - Trinidad e Tobago 9
TW - Taiwan 9
EE - Estonia 8
NP - Nepal 8
RO - Romania 8
CZ - Repubblica Ceca 7
KE - Kenya 7
LT - Lituania 7
PA - Panama 7
PR - Porto Rico 7
AL - Albania 6
AZ - Azerbaigian 6
BO - Bolivia 6
ET - Etiopia 6
KZ - Kazakistan 6
NI - Nicaragua 6
NO - Norvegia 6
BG - Bulgaria 5
BS - Bahamas 5
CI - Costa d'Avorio 5
DK - Danimarca 5
DO - Repubblica Dominicana 5
DZ - Algeria 5
HU - Ungheria 5
MK - Macedonia 5
RS - Serbia 5
TN - Tunisia 5
UY - Uruguay 5
BB - Barbados 4
KH - Cambogia 4
LB - Libano 4
MD - Moldavia 4
SY - Repubblica araba siriana 4
AM - Armenia 3
BH - Bahrain 3
LK - Sri Lanka 3
LV - Lettonia 3
OM - Oman 3
Totale 76.888
Salva come PNG Salva come JPEG
Città #
Woodbridge 12.784
Wilmington 12.544
Houston 12.279
Fairfield 2.729
Ashburn 2.024
Singapore 2.004
Ann Arbor 1.724
San Jose 1.248
Seattle 1.163
Chandler 910
Cambridge 889
Hong Kong 855
Jacksonville 841
Dublin 687
Beijing 625
Medford 531
Council Bluffs 485
Dearborn 461
Hangzhou 424
Kraków 403
Santa Clara 394
New York 358
Los Angeles 275
The Dalles 269
Ho Chi Minh City 246
Lawrence 238
Rome 208
Dallas 196
Tokyo 190
Lauterbourg 169
Zhengzhou 164
Hanoi 158
Buffalo 156
Helsinki 153
San Diego 142
Moscow 127
Menlo Park 120
Chicago 107
Milan 93
São Paulo 88
Mülheim 83
Colorado Springs 76
Naples 75
San Francisco 59
Denver 58
Toronto 58
London 57
Monte Vista 57
Norwalk 57
Redwood City 57
Phoenix 53
Montreal 52
Brooklyn 50
Shanghai 50
Atlanta 49
Cardiff 47
Columbus 47
Detroit 47
Boardman 46
Mountain View 46
Redondo Beach 45
Verona 43
Jakarta 42
Orem 41
Guangzhou 40
Hefei 39
San Mateo 37
Nanjing 34
Rio de Janeiro 34
University Park 31
Belo Horizonte 29
Brasília 28
Nuremberg 28
Palo Alto 28
Warsaw 28
Falls Church 27
Kunming 27
Philadelphia 26
Stockholm 26
Boston 25
Brussels 25
Da Nang 25
Munich 25
Frankfurt am Main 24
Jinan 22
Saint Petersburg 22
Washington 22
Charlotte 21
Chennai 21
San José 21
Tashkent 21
Haiphong 19
Manchester 19
Mexico City 19
Queens 19
Guayaquil 18
Miami 18
Amsterdam 17
Curitiba 17
Poplar 17
Totale 61.655
Salva come PNG Salva come JPEG
Nome #
β2-Agonist Therapy in Lung Disease 566
Impact of N-Acetylcysteine on Mucus Hypersecretion in the Airways: A Systematic Review 539
An update on the pharmacotherapeutic management of lower respiratory tract infections 538
A systems medicine clinical platform for understanding and managing non- communicable diseases 528
Pharmacological characterisation of the interaction between glycopyrronium bromide and indacaterol fumarate in human isolated bronchi, small airways and bronchial epithelial cells 522
Pirfenidone, nintedanib and N-acetylcysteine for the treatment of idiopathic pulmonary fibrosis: A systematic review and meta-analysis 518
Asthma and COPD in an Italian adult population: Role of BMI considering the smoking habit 517
Interaction between corticosteroids and muscarinic antagonists in human airways 513
Drug safety evaluation of roflumilast for the treatment of COPD: a meta-analysis 510
Glucagon-like peptide 1 receptor: A novel pharmacological target for treating human bronchial hyperresponsiveness 508
Advances in asthma drug discovery: evaluating the potential of nasal cell sampling and beyond 502
Optimizing drug delivery in COPD: The role of inhaler devices 499
Can an increased cholinergic tone constitute a predictor of positive response to tiotropium in patients with moderate asthma? 498
A systematic review with meta-analysis of dual bronchodilation with LAMA/LABA for the treatment of stable COPD 497
Beyond lung function in COPD management: effectiveness of LABA/LAMA combination therapy on patient-centred outcomes. 495
Searching for the synergistic effect between aclidinium and formoterol: From bench to bedside 494
Effect of an additional dose of indacaterol in COPD patients under regular treatment with indacaterol. 493
An unusual outbreak of nontuberculous mycobacteria in hospital respiratory wards: Association with nontuberculous mycobacterial colonization of hospital water supply network 492
Onset of action of budesonide/formoterol Spiromax® compared with budesonide/formoterol Turbuhaler® in patients with COPD 492
Airflow obstruction: Is it asthma or is it COPD? 491
Asthma and comorbid medical illness. 489
LABA/LAMA combination in copd: A meta-analysis on the duration of treatment 489
Impact of Mucolytic Agents on COPD Exacerbations: A Pair-wise and Network Meta-analysis 485
Pharmacological investigation on the anti-oxidant and anti-inflammatory activity of N-acetylcysteine in an ex vivo model of COPD exacerbation 480
Withdrawal of inhaled corticosteroids in COPD: A meta-analysis 480
Management of Chronic Obstructive Pulmonary Disease in Patients with Cardiovascular Diseases 480
High glucose enhances responsiveness of human airways smooth muscle via the Rho/ROCK pathway. 475
Impact of LABA/LAMA combination on exercise endurance and lung hyperinflation in COPD: A pair-wise and network meta-analysis 472
Safety of humanized monoclonal antibodies against IL-5 in asthma: focus on reslizumab 471
Safety Considerations with Dual Bronchodilator Therapy in COPD: An Update 470
Safety of inhaled corticosteroids for treating chronic obstructive pulmonary disease 469
Bacterial extracts for the prevention of acute exacerbations in chronic obstructive pulmonary disease: A point of view 466
Umeclidinium for the treatment of chronic obstructive pulmonary disease 459
Umeclidinium bromide + vilanterol for the treatment of chronic obstructive pulmonary disease 458
Therapeutic Monoclonal Antibodies for the Treatment of Chronic Obstructive Pulmonary Disease 457
Metabolic syndrome and risk of pulmonary involvement 455
Chronic obstructive pulmonary disease and coronary disease: COPDCoRi, a simple and effective algorithm for predicting the risk of coronary artery disease in COPD patients 455
The prevalence of asthma and COPD in Italy: a practice-based study 454
Tiotropium formulations and safety: a network meta-analysis 454
Asthma and comorbid medical illness 453
Treatment options for moderate-to-very severe chronic obstructive pulmonary disease 453
Role of muscarinic antagonists in asthma therapy 452
Bronchodilator therapy for chronic cough 452
Influence of N-acetylcysteine on chronic bronchitis or COPD exacerbations: a meta-analysis 451
A safety comparison of LABA+LAMA vs LABA+ICS combination therapy for COPD 451
Cardiovascular disease in asthma and COPD: A population-based retrospective cross-sectional study 444
Muscarinic receptor antagonists for the treatment of chronic obstructive pulmonary disease 444
QVA149 (indacaterol/glycopyrronium) for the treatment of chronic obstructive pulmonary disease 444
Effect of indacaterol on arterial blood gases in patients suffering from acute exacerbation of COPD 443
An overview of the current management of chronic obstructive pulmonary disease: can we go beyond the GOLD recommendations? 442
New Treatments for COPD in the Elderly 441
Pharmacological characterization of the interaction between the dual phosphodiesterase (PDE) 3/4 inhibitor RPL554 and glycopyrronium on human isolated bronchi and small airways 441
The Time Course of Pulmonary Function Tests in COPD Patients with Different Levels of Blood Eosinophils 441
The Challenges of Precision Medicine in COPD 441
Pharmacological characterization of the interaction between umeclidinium and vilanterol in human bronchi 439
Defining Phenotypes in COPD: An Aid to Personalized Healthcare 437
Epithelium integrity is crucial for the relaxant activity of brain natriuretic peptide in human isolated bronchi 435
The effect of indacaterol during an acute exacerbation of COPD 434
Evaluation of the effects of the R- and S-enantiomers of salbutamol on equine isolated bronchi 433
Chronic treatment with indacaterol and airway response to salbutamol in stable COPD 433
Pharmacological assessment of the onset of action of aclidinium and glycopyrronium versus tiotropium in COPD patients and human isolated bronchi 430
Effect of adding roflumilast or ciclesonide to glycopyrronium on lung volumes and exercise tolerance in patients with severe COPD: A pilot study 430
Bacterial lysates as a potentially effective approach in preventing acute exacerbation of COPD. 429
Translational study searching for synergy between glycopyrronium and indacaterol 429
A pilot comparison of helium dilution and plethysmographic lung volumes to assess the impact of a long-acting bronchodilator on lung hyperinflation in COPD 428
Change in asthma and COPD prescribing by Italian general practitioners between 2006 and 2008 426
Adherence to COPD treatment: Myth and reality 425
Cardiovascular disease in asthma and COPD: a population-based retrospective cross-sectional study 424
Biomarkers of lung damage associated with tobacco smoke in induced sputum 424
The discovery of roflumilast for the treatment of chronic obstructive pulmonary disease 423
Comorbidities of asthma 421
Do we really need asthma-chronic obstructive pulmonary disease overlap syndrome? 421
Relaxant effect of brain natriuretic peptide in nonsensitized and passively sensitized isolated human bronchi 419
Pharmacological modulation of beta-adrenoceptor function in patients with coexisting chronic obstructive pulmonary disease and chronic heart failure 417
Escalation and De-escalation of Therapy in COPD: Myths, Realities and Perspectives 417
Effect of the Mixed Phosphodiesterase 3/4 Inhibitor RPL554 on Human Isolated Bronchial Smooth Muscle Tone 415
Treating systemic effects of COPD 413
Emerging biological therapies for treating chronic obstructive pulmonary disease: A pairwise and network meta-analysis 411
Influence of ethnicity on response to asthma drugs 410
Aclidinium bromide/formoterol fumarate fixed-dose combination for the treatment of chronic obstructive pulmonary disease 409
Indacaterol for the treatment of chronic obstructive pulmonary disease 406
The clinical use of regenerative therapy in COPD 402
Can bronchial asthma with an highly prevalent airway (and systemic) vagal tone be considered an independent asthma phenotype? Possible role of anticholinergics 400
Olodaterol + tiotropium bromide for the treatment of chronic obstructive pulmonary disease 399
LABA/LAMA combinations instead of LABA/ICS combinations may prevent or delay exacerbations of COPD in some patients 396
The effect of N-acetylcysteine on biofilms: Implications for the treatment of respiratory tract infections 395
Cardiovascular disease in patients with COPD 390
Brain natriuretic peptide protects against hyperresponsiveness of human asthmatic airway smooth muscle via an epithelial cell-dependent mechanism 385
Diabetes mellitus among outpatients with COPD attending a university hospital. 384
Beclomethasone dipropionate and formoterol fumarate synergistically interact in hyperresponsive medium bronchi and small airways 383
An update on bronchodilators in Phase I and II clinical trials 379
Eosinophilic pneumonia in an asthmatic patient treated with omalizumab therapy: Forme-fruste of Churg-Strauss syndrome? 376
COPD diagnosis by a gas sensor array 376
Biomarkers in COPD 376
Contribution of sensory nerves to LPS-induced hyperresponsiveness of human isolated bronchi 373
Targeting Mechanisms Linking COPD to Type 2 Diabetes Mellitus 373
Long‑term management of patients with chronic obstructive pulmonary disease who undergo percutaneous coronary intervention still needs to be dramatically improved 372
Phosphodiesterase inhibitors for chronic obstructive pulmonary disease: what does the future hold? 372
Brain natriuretic peptide: Much more than a biomarker 370
In stable COPD, long-acting muscarinic antagonist plus long-acting beta-agonists resulted in less exacerbations, pneumonia and larger improvement in FEV 1 than long-acting beta-agonists plus inhaled corticosteroids 369
Totale 44.531
Salva come PNG Salva come JPEG
Categoria #
all - tutte 207.574
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 207.574
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.868 0 0 0 55 77 259 145 109 133 271 159 660
2022/20232.677 348 150 54 319 239 662 248 172 235 19 161 70
2023/2024889 192 27 68 11 85 212 61 38 16 34 12 133
2024/20255.845 217 1.349 622 318 184 206 510 321 538 548 565 467
2025/20269.902 649 503 1.208 739 889 317 1.273 1.156 1.385 713 617 453
2026/20274.165 1.031 482 2.053 599 0 0 0 0 0 0 0 0
Totale 77.609